Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

More documents

Recommendations

Info

FNEA 57115 NEEVP 84162 NMOC 83936 PURKINJE CELL CYTOPLASMIC ANTIBODY, Type Tr (PCA-Tr)
NMOER 60796 optic nerves and the spinal cord, typically spares the brain, and generally follows a relapsing course. Within 5 years, 50% of patients lose functional vision in at least 1 eye or are unable to walk independently. In North America, the proportion of nonwhite individuals is higher among patients with NMO than among those with classic multiple sclerosis. During acute attacks, the cerebrospinal fluid contains inflammatory cells, but often lacks evidence of intrathecal IgG synthesis. Many patients with NMO are misdiagnosed as having multiple sclerosis, due to earlier misconceptions that NMO was a monophasic disorder, and was not associated with brain imaging abnormalities. Importantly the prognosis and optimal treatments for the 2 diseases differ. NMO typically has a worse outcome than multiple sclerosis, with frequent and early relapses. Plasmapheresis is more beneficial for patients with NMO than for those with multiple sclerosis. Early diagnosis and treatment are important to reduce the morbidity of NMO. Seropositivity for NMO autoantibody IgG (NMO-IgG) allows early diagnostic distinction between NMO (73% positive; 91% specific) and multiple sclerosis (0% positive). NMO-IgG is uniformly negative in patients with classical multiple sclerosis, for which no biomarker is currently recognized. This distinction is important both prognostically and therapeutically, because optimal treatments differ for NMO (immunosuppression) and multiple sclerosis (immunomodulation with beta-IFN or glatiramer acetate). Useful For: Establishing the diagnosis of neuromyelitis optica (NMO) and related disorders (eg, relapsing transverse myelitis or relapsing optic neuritis), predicting with 60% probability, relapse or progression to NMO in patients presenting with an initial episode of longitudinally extensive transverse myelitis. Seropositivity distinguishes these disorders from multiple sclerosis early in the course of disease. This allows initiation and maintenance of optimal therapy. Serum is the preferred specimen for detection of NMO-IgG (see #60796 Neuromyelitis Optica (NMO) Evaluation with Reflex, Serum); cerebrospinal fluid is usually less informative. Interpretation: A positive value is consistent with NMO or a related disorder, and justifies initiation of appropriate immunosuppressive therapy at the earliest possible time. Our prospective studies have revealed that 40% of adult patients with longitudinally-extensive transverse myelitis are seropositive and, of that group, 60% relapse or progress to NMO within 2 years. No seronegative patient relapsed in up to 7 years of follow-up. Reference Values: Negative Clinical References: 1. Wingerchuk DM, Lennon VA, Pittock SJ, et al: Revised diagnostic criteria for neuromyelitis optica. Neurol 2006;66:1485-1489 2. Kerr DA: The lumping and splitting of inflammatory CNS diseases. Neurol 2006;66:1466-1467 3. Luccinnetti CF, Mandler RN, McGavern D, et al: A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-1461 3. Cross SA, Salomao DR, Parisi JE, et al: Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003;54:38-50 5. Cross SA, Salomao DR, Parisi JE, et al: Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Am J Ophthalmol 2003;136(6):1200 (abstract) Neuromyelitis Optica (NMO) Evaluation with Reflex, Serum Clinical Information: Neuromyelitis optica (NMO, sometimes called Devic disease) is a severe, relapsing, autoimmune, inflammatory and demyelinating central nervous system disease that predominantly affects optic nerves and the spinal cord. The disorder is now recognized as a spectrum of autoimmunity targeting the astrocytic water channel aquaporin-4 (AQP4). NMO spectrum disorders (NMOSD) may involve the brain and brainstem with symptoms of encephalopathy (particularly in children). The initial symptoms may be bouts of intractable nausea and vomiting. Magnetic resonance imaging typically reveals large inflammatory spinal cord lesions involving 3 or more vertebral segments. During acute attacks, the cerebrospinal fluid contains inflammatory cells, but usually lacks evidence of intrathecal IgG synthesis. The clinical course is characterized by relapses of optic neuritis or transverse myelitis, or both. Prior to introducing a serological biomarker for NMO, the disorder was thought to be confined exclusively to the optic nerves and spinal cord, that the clinical course was monophasic and that NMO was a subset of multiple sclerosis (MS). The discovery of a highly specific disease marker for NMO (NMO-IgG/AQP4-IgG) helped to define the full clinical spectrum of NMOSD and to distinguish Current as of January 3, 2013 2:22 pm CST 800-533-1710 or 507-266-5700 or <strong>Mayo</strong><strong>Medical</strong>Laboratories.com Page 1304
Page 1 and 2:
Rochester 2013 Interpretive Handboo
Page 3 and 4:
Policies - Mayo Medical Laboratorie
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
TTIG 82506 DHVD 8822 Tetanus Toxoid
Page 15 and 16:
DCRN 8847 not without risk, and is
Page 17 and 18:
DOC 8547 defect has selectively aff
Page 19 and 20:
FDSOX 91690 THCM 84284 11-Desoxycor
Page 21 and 22:
FBP1 86208 these modified WHO crite
Page 23 and 24:
17OHP 81151 exaggerated responses t
Page 25 and 26:
OHPG 9231 mass spectrometry. Horm R
Page 27 and 28:
FP73 88541 requiring differentiatio
Page 29 and 30:
Useful For: As an adjunct to measur
Page 31 and 32:
CYPKP 89082 challenge because most
Page 33 and 34:
25HDN 83670 Clinical References: 1.
Page 35 and 36:
FLUC 82741 F5HAR 57333 Salt Lake Ci
Page 37 and 38:
6MAMM 89659 6MAMU 89605 6-Monoacety
Page 39 and 40:
ACAC 82757 8-MOP blood levels. Beca
Page 41 and 42:
ACM 8698 sensitization to particula
Page 43 and 44:
ACHE_ 9287 ACHS 8522 Reference Valu
Page 45 and 46:
SAFB 8213 ACT 8221 the era of enzym
Page 47 and 48:
AHPS 9022 catalyzes APC inactivatio
Page 49 and 50:
AHEPR 86137 hepatitis B virus infec
Page 51 and 52:
FACY 90308 ACRN 82413 Acyclovir, Se
Page 53 and 54:
1-7 days:
Page 55 and 56:
demonstrate mild and intermittent b
Page 57 and 58:
ADMIS 61213 ADA 80649 FADA 91554 Re
Page 59 and 60:
FAAST 57116 FADE 91670 LADV 89074 A
Page 61 and 62:
FAPG 91347 FADMK 91925 RACTH 82140
Page 63 and 64:
FAERO 91865 AGXMS 89915 Clinical Re
Page 65 and 66:
AGXKM 89916 E, Rumsby G: Selected e
Page 67 and 68:
AGXT 83643 FALUF 57286 ALB Referenc
Page 69 and 70:
FALCO 90084 ALS 8363 This specimen
Page 71 and 72:
ALAV 6349 ARAV 6348 ALDS 8557 ALDU
Page 73 and 74:
esponse to cholestatic liver diseas
Page 75 and 76:
11 years: 185-507 U/L 12 years: 185
Page 77 and 78:
FALMD 92001 ALM 82882 the dietary t
Page 79 and 80:
FASU 91221 CD8 (double-negative T c
Page 81 and 82:
A1ATR 83050 1981;81:777-780 2. Cros
Page 83 and 84:
AAT 8161 A1M24 81036 1981;81:777-78
Page 85 and 86:
A2M 9270 biological half-life of ap
Page 87 and 88:
AFP 8162 might be found in chronic
Page 89 and 90:
MAFP 81169 interpreted with caution
Page 91 and 92:
FUCT 8815 Useful For: Screening for
Page 93 and 94:
AGA 8785 from deficient activity of
Page 95 and 96:
AGPB 9499 third decade with the dev
Page 97 and 98:
IDSBS 60617 =1.0 nmol/h/mL) are not
Page 99 and 100:
MANT 8773 Clinical Information: Cli
Page 101 and 102:
ANAS 8782 degraded GAG (also called
Page 103 and 104:
proportion of these cases, free alp
Page 105 and 106:
ALU 8828 and to define the allergen
Page 107 and 108:
Clinical Information: Under normal
Page 109 and 110:
TFE3 61013 alone, especially true w
Page 111 and 112:
AMIKR 81752 AMIKT 81593 Drugs.Clini
Page 113 and 114:
Clinical Information: Amino acids a
Page 115 and 116:
findings, and physical and cognitiv
Page 117 and 118:
Useful For: Evaluating patients wit
Page 119 and 120:
ALAUR 61547 Reference Values: GLUTA
Page 121 and 122:
ALAD 88924 Interpretation: In patie
Page 123 and 124:
AFC 80334 AMOBS 8325 correlate with
Page 125 and 126:
AMPCS 61518 clinical manifestations
Page 127 and 128:
AMPHM 84371 FAMPH 90113 Amphetamine
Page 129 and 130:
FAMPB 91994 AMPHB 80429 AMP 82664 P
Page 131 and 132:
AMLPC 60078 PAMYB 5079 12-17 months
Page 133 and 134:
AMSU 8356 Thus, conditions associat
Page 135 and 136:
FABP 91408 82091 Reference Values:
Page 137 and 138:
TTRX 83674 identified within the TT
Page 139 and 140:
FPGO 57160 ANCH 82345 Anaplasma pha
Page 141 and 142:
conjunction with measurement of oth
Page 143 and 144:
FACE 90447 ACE 8285 Interpretation:
Page 145 and 146:
ANSE 82487 Clinical Information: Cl
Page 147 and 148:
IGAAB 8154 FIGER 91788 Patients wit
Page 149 and 150:
ABID2 8988 ABSCM 8956 ABTIH 9000 Te
Page 151 and 152:
FASUQ 57517 FADS 91720 RIF 80430 MM
Page 153 and 154:
ZMMLS 8073 MMLSA 56031 Useful For:
Page 155 and 156:
MTBV2 56032 MMLNS 82019 Med 2006;17
Page 157 and 158:
FANTU 91146 AMH 89711 Antimony, Uri
Page 159 and 160:
ANAH2 86038 (ANCA) and cANCA or pAN
Page 161 and 162:
deficiency are usually heterozygous
Page 163 and 164:
APO1S 60723 levels by 180 days post
Page 165 and 166:
APO2S 60725 APO2K 60726 Apolipoprot
Page 167 and 168:
APLB 80308 APOB 89097 Reference val
Page 169 and 170:
APPL 82712 populations are as follo
Page 171 and 172:
AWNS 87814 AWNC 87813 Arbovirus and
Page 173 and 174:
ABOPC 83897 may be influenced by ag
Page 175 and 176:
AVP 80344 ST. LOUIS ENCEPHALITIS AN
Page 177 and 178:
CGH 88898 Changes that are inherite
Page 179 and 180:
ARSAK 61260 ASFR 80375 Gieselmann V
Page 181 and 182:
ASU 8644 0-24 mcg/L Reference value
Page 183 and 184:
ASNA 89848 ASRU 89889 present in ha
Page 185 and 186:
ARST 8778 The gastrointestinal trac
Page 187 and 188:
ARSU 8777 Useful For: Detection of
Page 189 and 190:
VITC 60296 immune response to aller
Page 191 and 192:
lag, macrocephaly, and hypotonia. D
Page 193 and 194:
ASPAG 84356 Useful For: The determi
Page 195 and 196:
ASP 82911 Useful For: As an aid in
Page 197 and 198:
ADMA 83651 Useful For: Testing for
Page 199 and 200:
FAPPN 57142 AUPU 82855 crossreactiv
Page 201 and 202:
ADE 89904 Interpretation: Detection
Page 203 and 204:
(GI) motility studies (eg, gastric,
Page 205 and 206:
FADAE 91584 ARPKD 88911 MITOCHONDRI
Page 207 and 208:
AVOC 82812 FAZAT This result must b
Page 209 and 210:
CD40 89009 cytogenetics in hematolo
Page 211 and 212:
IABCS 88800 Reference Values: An in
Page 213 and 214:
Results Expressed as a Percentage o
Page 215 and 216:
65 years: < or =59 pg/mL 66 years:
Page 217 and 218:
PBAB 81147 may have hepatomegaly an
Page 219 and 220:
SPUT 8095 UR 8105 ANAE 84292 Bacter
Page 221 and 222:
EPRP 60235 PFGE 80349 chronically i
Page 223 and 224:
BCYP 82722 0 Negative 1 0.35-0.69 E
Page 225 and 226:
BARBU 80372 clinical manifestations
Page 227 and 228:
BRLY 82687 20405 Clinical Reference
Page 229 and 230:
BART 81575 BARRP 84440 Cypress, CA
Page 231 and 232:
BASL 82489 FBBLK 91983 August;2(10)
Page 233 and 234:
BA190 83336 fusion variants (e20/a2
Page 235 and 236:
MBCR 80578 BAKDM 89609 BCR/ABL, Tra
Page 237 and 238:
FBEAN 91646 FBLMA 91963 BWSRS 61010
Page 239 and 240:
BREG 82692 bronchospasm) in infants
Page 241 and 242:
BEETS 82618 FQFKL 57294 6 > or =100
Page 243 and 244:
BENZU 80370 Blood benzene concentra
Page 245 and 246:
BERG 82892 3 3.50-17.4 Positive 4 1
Page 247 and 248:
B2GP1 88894 manifestations, includi
Page 249 and 250:
MB2GP 86181 systemic rheumatic dise
Page 251 and 252:
B2OSH 300245 B2MC of CSF into the n
Page 253 and 254:
B2M 9234 CTX 83175 and correction f
Page 255 and 256:
BGABS 60986 presents at a later ons
Page 257 and 258:
BGA 8486 (also known as mucopolysac
Page 259 and 260:
BGL 8788 spots, and/or fibroblasts
Page 261 and 262:
the beta subunit of LH and acts thr
Page 263 and 264:
BLACT 8118 BLAC 82896 Beta-Lactamas
Page 265 and 266:
FBIU 90357 9880 FBAF 91701 concentr
Page 267 and 268:
19701 BILID 81787 (non-PSC vs. PSC
Page 269 and 270:
BILI3 8452 permeability is increase
Page 271 and 272:
BTDMS 89012 excretion are impaired
Page 273 and 274:
BIOTS 88205 inherited in an autosom
Page 275 and 276:
LCBKP 89982 DNA-containing viruses
Page 277 and 278:
QBKU 87859 BLPEP 82814 polyomavirus
Page 279 and 280:
SBLAS 86691 CBLAS 89986 responsible
Page 281 and 282:
80326 BDIAL 83094 BTROP 82374 Washi
Page 283 and 284:
UEBF 81834 BWOR 82840 to the nature
Page 285 and 286:
BLUE 82359 of allergic reactions to
Page 287 and 288:
BHINT 9027 BHQL osteomalacia, and o
Page 289 and 290:
FBPTS 57290 for sensitive and rapid
Page 291 and 292:
BOT 82715 BOV 82135 Botrytis cinere
Page 293 and 294:
89045 BRAFM 83837 0 Negative 1 0.35
Page 295 and 296:
BRAZ 82899 therapies directed to co
Page 297 and 298:
FYSTB 91990 BROC 82817 Useful For:
Page 299 and 300:
BRM 8608 BRUGM 89476 Clinical Refer
Page 301 and 302:
BRUTA 8112 BSPR 82480 Reference Val
Page 303 and 304:
affects the severity of the clinica
Page 305 and 306:
in the mothers of 35 of the 41 pati
Page 307 and 308:
BTKK 89306 mutations in female rela
Page 309 and 310:
BUCW 82727 presentation. Females ar
Page 311 and 312:
BFTH 82779 likelihood of allergic d
Page 313 and 314:
BUPIS 89548 BUPM 500038 Bupivacaine
Page 315 and 316:
FBUS 91115 BUAUC 83188 Buspirone (B
Page 317 and 318:
FCPEP 91270 situations, insulin lev
Page 319 and 320:
C1ES 8198 Useful For: Assessment of
Page 321 and 322:
C1QFX 83374 Reference Values: C1Q B
Page 323 and 324:
C2 81835 peptides that are chemotac
Page 325 and 326:
FC3D 91725 C4U 88829 C4FX 83391 Adv
Page 327 and 328:
C5FX 83392 C5DCU 88831 Clinical Ref
Page 329 and 330:
C6FX 83393 C7FX 81064 C6 Complement
Page 331 and 332:
C9FX 81066 CABB 33-58 U/mL Clinical
Page 333 and 334:
CDOMB 89539 CDOM 80595 and to defin
Page 335 and 336:
CDB 8682 CDRU 60156 Administration,
Page 337 and 338:
2 9.2-13.7
Page 339 and 340:
FCAH1 91275 5 12.8-17.3 24-175 Test
Page 341 and 342:
17-Alpha-Hydroxyprogesterone, Serum
Page 343 and 344:
4 10.7-15.6 47-208 5 11.8-18.6 50-2
Page 345 and 346:
months to prepubertal levels. Prepu
Page 347 and 348:
Note: Luteal progesterone peaked fr
Page 349 and 350:
CATN 9160 Clinical References: 1. T
Page 351 and 352:
CSRMS 83703 mildly-to-moderately el
Page 353 and 354:
CAU 8594 apparent idiopathic hypopa
Page 355 and 356:
IONCG 300235 CAUR 60157 > or =18 ye
Page 357 and 358:
or =19 years: 8.9-10.1 mg/dL Refere
Page 359 and 360:
CAVPC 83900 reabsorption in the pro
Page 361 and 362:
FCALP 91597 FCAMP 91224 have been i
Page 363 and 364:
CANW 81780 bronchospasm) in infants
Page 365 and 366:
CDAB 82690 FCANA Reference Values:
Page 367 and 368:
FFTH 90479 FCAPR 90062 CWAY 82493 I
Page 369 and 370:
FCAR 81770 CAR 8654 Carbamazepine,
Page 371 and 372:
HODGE 89676 199PC 89508 199PT 61530
Page 373 and 374:
CA19 9288 CDG 89891 Interpretation:
Page 375 and 376:
CDTA 82425 CHOU 9255 glycosylation
Page 377 and 378:
CEAPT 61528 markers (ie, amylase an
Page 379 and 380:
CEASF 8918 CARD 82491 tissue. Usefu
Page 381 and 382:
FCRME 91660 CPTMS 61120 CPTKM 61121
Page 383 and 384:
CARNS 60449 > or =18 years 34-78 25
Page 385 and 386:
CACTS 61194 CACTK 61195 FREE 77-214
Page 387 and 388:
CARO 8288 CROT 82742 Carotene, Seru
Page 389 and 390:
CASH 82881 Class IgE kU/L Interpret
Page 391 and 392:
CAT 82665 COMTO 60336 by Laboratory
Page 393 and 394:
CATU 9276 action of MAO and COMT. P
Page 395 and 396:
CATP 8532 Clinical References: 1. Y
Page 397 and 398:
CALFL 82617 Not for clinical diagno
Page 399 and 400:
2-5 months: 10.0-14.0 g/dL 6 months
Page 401 and 402:
CD20B 89584 15 days-1 month: 2.50-1
Page 403 and 404:
TCD4 84348 Sources of variability i
Page 405 and 406:
CD4NY 28334 lymphocyte counts from
Page 407 and 408:
long-lived in the periphery and thi
Page 409 and 410:
may not necessarily correlate with
Page 411 and 412:
55 years: 31-409 cells/mcL Natural
Page 413 and 414:
CD8RT 89505 Reference Values: Inter
Page 415 and 416:
CDKKM 60229 and KIP2; maternally ex
Page 417 and 418:
CELY 82766 caused by the release of
Page 419 and 420:
antibodies. The treatment for celia
Page 421 and 422:
constipation.(2) Clinical symptoms
Page 423 and 424:
CBPA 8937 Clinical Information: Bod
Page 425 and 426:
CENTA 110006 CEAC 82387 Centromere
Page 427 and 428:
SFIN 8009 metachromatic leukodystro
Page 429 and 430:
80184 8032 disease and Menkes disea
Page 431 and 432:
CFTRM 88876 increased risk for a cl
Page 433 and 434:
FCCG 57274 CCHZ 82752 bronchospasm)
Page 435 and 436:
CHER 82798 Interpretation: Detectio
Page 437 and 438:
CNUT 82870 FCHIC 84308 Chestnut, Sw
Page 439 and 440:
CDROP 82142 3 3.50-17.4 Positive 4
Page 441 and 442:
CHIC 82703 sensitivity to inhalant
Page 443 and 444:
CHIDB 83182 CHEP 84427 CHRGB 83186
Page 445 and 446:
psittacosis, a disease characterize
Page 447 and 448:
CTRNA 61551 clinical signs and symp
Page 449 and 450:
MCRNA 61554 and in symptomatic male
Page 451 and 452:
CDP 8610 Alpha-Chlordane Synonym(s)
Page 453 and 454:
RCHLU 83747 CL 8460 Congenital chlo
Page 455 and 456:
FCHO 91157 CHLBF 82945 determined t
Page 457 and 458:
CHLE 8324 beta-LDL, alpha-1 HDL, al
Page 459 and 460:
CROMU 89547 CRU 8593 Test Performed
Page 461 and 462:
CGAK 34641 industry to make chromiu
Page 463 and 464:
AF 8426 cancer diagnosis. However,
Page 465 and 466:
CPG 89090 Useful For: Prenatal diag
Page 467 and 468:
BM 8506 chromosomally abnormal clon
Page 469 and 470:
CTI 8425 TUMOR 80258 exchange (SCE)
Page 471 and 472:
FCSP 80602 PF 8912 Chromosome Anoma
Page 473 and 474:
CHSUP 9025 hepatitis B virus infect
Page 475 and 476:
CHUB 82822 lymphocytic leukemia. Br
Page 477 and 478:
CINN 82624 FCIC 91497 Clinical Refe
Page 479 and 480:
CTCP 60142 CITAL 83730 peripheral b
Page 481 and 482:
CLAD 82912 Reference Values: 0-19 y
Page 483 and 484:
FCLIN 80143 PCLLM 20437 responsible
Page 485 and 486:
FCLOZ 57284 FCLOM 57276 CLONS 50010
Page 487 and 488:
CLOV 82490 variability underlying t
Page 489 and 490:
F_2 9121 F2IS 7805 250 to 500 copie
Page 491 and 492:
F5IS 7807 activated partial thrombo
Page 493 and 494:
F8A 9070 F_10 9066 Coagulation Fact
Page 495 and 496:
F_11 9067 F11IS 7803 Useful For: De
Page 497 and 498:
CORU 60354 Richards Company, Tricon
Page 499 and 500:
COBCU 60353 FCOCB 90093 COKEM 84140
Page 501 and 502:
FCOCC 57355 SCOC 8295 within the pa
Page 503 and 504:
CIMRP 88804 rarely found in CSF. Ho
Page 505 and 506:
CCNT 82739 testing often depend upo
Page 507 and 508:
Q10 87853 5 50.0-99.9 Strongly posi
Page 509 and 510:
CTF 80440 CMIL 82833 Colorado Tick
Page 511 and 512:
C1Q 8851 activated T cells(2) -TACI
Page 513 and 514:
AH50 88676 COM 8167 congenital C4 d
Page 515 and 516:
FCMD 91452 CAHBS 84113 Test Perform
Page 517 and 518:
low or undetectable. All 3 analytes
Page 519 and 520:
CUU 8590 Reference Values: ANTINUCL
Page 521 and 522:
CURU 60426 CUS 8612 test results, c
Page 523 and 524:
CORI 82476 leakage through the kidn
Page 525 and 526:
CORN 82705 FCRN4 91982 Clinical Ref
Page 527 and 528:
17-Hydroxyprogesterone, Serum - DHE
Page 529 and 530:
FCBGC 91673 hydrocortisone) increas
Page 531 and 532:
CIVC 6347 CLAV 6346 CRAV 6345 SALCT
Page 533 and 534:
CINP 9369 diagnosis of Cushing synd
Page 535 and 536:
enzyme that converts cortisol to co
Page 537 and 538:
CDIP 89860 COTT 82859 0-2 years: no
Page 539 and 540:
CTWD 82748 Interpretation: Detectio
Page 541 and 542:
FACX 91340 COXA 80248 FBCX 91341 Co
Page 543 and 544:
CPOXK 61264 constipation, urinary r
Page 545 and 546:
CRAY 82343 caused by the release of
Page 547 and 548:
CKEL 80906 32 days-23 months 313-90
Page 549 and 550:
CRC 8500 CK activity reaches a maxi
Page 551 and 552:
listed in the following paragraphs:
Page 553 and 554:
CTU 8513 FCDC clearance of creatini
Page 555 and 556:
CRY_S 80988 FCRYP 90453 Reference V
Page 557 and 558:
CRYPF 60320 SCRYR 28071 Interpretat
Page 559 and 560:
CRYPS 80335 SFC 8719 Clinical Infor
Page 561 and 562:
OATC 82916 sensitization to particu
Page 563 and 564:
WHTC 82915 FUNID 8223 Cultivated Wh
Page 565 and 566:
CURL 82852 testing often depend upo
Page 567 and 568:
CIFS 8052 8041 rearrangement of the
Page 569 and 570:
GRP 8771 CCP 84182 derived from veg
Page 571 and 572:
CYCSP 8931 CSTC 82994 Reference Val
Page 573 and 574:
CYSWB 81354 Exon 15: Q890X Exon 6b:
Page 575 and 576:
CYSR 81067 CYSTINE 3-15 years: 11-5
Page 577 and 578:
environmental factors. Useful For:
Page 579 and 580:
2C19S 60439 to affect CYP1A2 activi
Page 581 and 582:
2C19O 60335 Cytochrome P450 2C19 Ge
Page 583 and 584:
2C9SO 60337 Useful For: Predicting
Page 585 and 586:
elationship between the polymorphis
Page 587 and 588:
2D6TO 60340 flashes that accompany
Page 589 and 590:
2D6O 60334 Cytochrome P450 2D6 Geno
Page 591 and 592:
3A4O 61242 Useful For: An aid to cl
Page 593 and 594:
CMG 80750 may have primary CMV infe
Page 595 and 596:
Clinical Information: Cytomegalovir
Page 597 and 598:
determining over immunosuppression
Page 599 and 600:
QCMV 82986 ANCA 9441 Rev 2000;13:83
Page 601 and 602:
DLAC 8878 Useful For: Diagnosis of
Page 603 and 604:
DAND 82694 Class IgE kU/L Interpret
Page 605 and 606:
DATRE 82481 9803 6 > or =100 Strong
Page 607 and 608:
DHEA/DHEAS and their 16-hydroxylate
Page 609 and 610:
Interpretation: Elevated dehydroepi
Page 611 and 612:
DRPLA 81801 FDOC 90134 the immune r
Page 613 and 614:
DESIP 81854 clinical manifestations
Page 615 and 616:
83365 FDXM 91956 1):167-170 2. Amag
Page 617 and 618:
DIA 8629 type 1 diabetes. Only 2% t
Page 619 and 620:
DIG 8674 free digoxin levels daily
Page 621 and 622:
DHT remain normal with aging, despi
Page 623 and 624:
FDILT 91118 FRVVT 91738 DIP 83262 6
Page 625 and 626:
DLDL 200269 FDSAC 91414 FDISP 91595
Page 627 and 628:
FDM1 91592 ADNA 8178 FDKYL DM1 DNA
Page 629 and 630:
DRD3O There has been a strong assoc
Page 631 and 632:
DRD4 89096 DRD4O 60344 Dopamine Rec
Page 633 and 634:
DOXP 9301 FDOXY 90061 Class IgE kU/
Page 635 and 636:
CDAU2 80918 intended to be used in
Page 637 and 638:
CDAU 9446 confirmed by GC-MS or GC-
Page 639 and 640:
DAAMP 505341 mass spectrometry (LC-
Page 641 and 642:
DAUCO 505230 DMETH 505343 triazolam
Page 643 and 644:
DPRP 505345 propoxyphene are >10,00
Page 645 and 646:
CDAG 500755 DSS 8421 Propoxyphene 7
Page 647 and 648:
PDSU 88760 FBDAS 91776 Molecular Di
Page 649 and 650:
DAU9 505320 DASM4 60553 Results of
Page 651 and 652:
DUCK 82708 DULOX 89305 Phencyclidin
Page 653 and 654:
EEEP 83155 ESYC 82721 2. Donat JF,
Page 655 and 656:
FECHC 91342 sensitization and clini
Page 657 and 658:
FEGFR 91903 FEGGW 91976 EGG 82872 U
Page 659 and 660:
EGGP 82477 wheat proteins) followed
Page 661 and 662:
FECHA 91710 EHRL 84319 the prevalen
Page 663 and 664:
ELDR 82392 Elastase has been implic
Page 665 and 666:
EFP 81488 > or =16 years: 0-29 mEq/
Page 667 and 668:
REPU 60068 PEL 80085 Electrophoresi
Page 669 and 670:
ELM 82672 Interpretation: A charact
Page 671 and 672:
or = 1:1 Antibody Detected Diagnosi
Page 673 and 674:
FJAZ 61014 5362 FEMA Endometrial St
Page 675 and 676:
SAM 9049 caused by the release of p
Page 677 and 678:
FENT 91434 FENTQ 91312 Diagnosis of
Page 679 and 680:
EOSU 8335 FEPHD 90109 EPUR 82854 In
Page 681 and 682:
EPIP2 81881 3 3.50-17.4 Positive 4
Page 683 and 684:
80786 several weeks to months after
Page 685 and 686:
LEBV 81239 onset of the infection,
Page 687 and 688:
REVP 84160 Useful For: A prospectiv
Page 689 and 690:
EPOR 61679 Chronic renal failure pa
Page 691 and 692:
EEST 81816 levels of
Page 693 and 694:
well-nourished children. Inherited
Page 695 and 696:
89213 ESTF 84230 information, in ad
Page 697 and 698:
should be within the reference rang
Page 699 and 700:
E1 81418 Stage IV 12.3 years 15-85
Page 701 and 702:
Males may show delayed puberty and
Page 703 and 704:
ETOHU 500323 ETX 8769 Interpretatio
Page 705 and 706:
EOXD 82767 EUCL 82758 Ethylene Oxid
Page 707 and 708:
EHOR 82662 Reference Values: Class
Page 709 and 710:
83363 transcripts by reverse transc
Page 711 and 712:
FABKM 88266 F9INH 83103 Fabry Disea
Page 713 and 714:
F8INH 83102 FX13M 57302 anticoagula
Page 715 and 716:
FAPKM 83001 clinical manifestations
Page 717 and 718:
FD 85319 LDLRS 81013 clinical pheno
Page 719 and 720:
LDLM 89073 19p13 and consists of 18
Page 721 and 722:
FANCA 85318 or more mutations in in
Page 723 and 724:
FAPCP 82042 progress to evaluate th
Page 725 and 726:
Myristoleic Acid, C14:1 or =18 yea
Page 727 and 728:
1-17 years: 50-130 nmol/mL > or =18
Page 729 and 730:
Palmitic Acid, C16:0 or =18 years:
Page 731 and 732:
FAPM 81939 > or =18 years: 0.2-0.5
Page 733 and 734:
POX 81369 Stearic Acid, C18:0 or =
Page 735 and 736:
FBN1 89308 prolapse. There is signi
Page 737 and 738:
FETH2 81880 prenatal, and family co
Page 739 and 740:
LEU 8046 FOBT 60693 Fecal Leukocyte
Page 741 and 742:
FESE 82363 FENTU 89655 therapeutic
Page 743 and 744:
FEEP 82143 FERR 8689 Clinical Refer
Page 745 and 746:
FECHK 60372 by 50% can be identifie
Page 747 and 748:
FMB 88841 FMBNY 30320 Fetomaternal
Page 749 and 750:
FGAKM 60722 secondary to multiple m
Page 751 and 752:
FIBR 8482 FBC 80333 number of acqui
Page 753 and 754:
FFIL4 90068 Complete removal can be
Page 755 and 756:
FANT 82698 0 Negative 1 0.35-0.69 E
Page 757 and 758:
produced by the fetus and the place
Page 759 and 760:
FLUCO 82522 FFLRO 91795 FL 8641 Flu
Page 761 and 762:
PROLX 80458 FFLUR 90091 17BFP 89739
Page 763 and 764:
FSH 8670 patients with neuropsychia
Page 765 and 766:
9806 FOOD6 81874 FDP1 86207 Fontana
Page 767 and 768:
FOOD4 81872 and to define the aller
Page 769 and 770:
FOOD8 81876 FOOD1 81868 Company, 20
Page 771 and 772:
FOOD3 81871 Reference Values: Class
Page 773 and 774:
FFRM 90298 9881 60694 Normal: Avera
Page 775 and 776:
FXPB 9569 6 > or =100 Strongly posi
Page 777 and 778:
FRTIX 80315 FFRED 91819 Free Thyrox
Page 779 and 780:
FRUCT 81610 FROS 81164 FA have repe
Page 781 and 782:
FSS 83121 error of folate and histi
Page 783 and 784:
FDERM 87283 FGEN 84389 FVAG If posi
Page 785 and 786:
FFURO 91119 FUSM 82750 species such
Page 787 and 788:
GABCC 61515 GABA 80826 Interpretati
Page 789 and 790:
GDT 89302 GDUR 89316 gadobenate dim
Page 791 and 792:
GDCRU 60428 after administration of
Page 793 and 794:
GALU 8765 Interpretation: In patien
Page 795 and 796:
GALT 8333 Galactose-1-Phosphate Uri
Page 797 and 798:
GAL6 84366 galactose-a-1,3-galactos
Page 799 and 800:
GCT 84360 Galactosemia Reflex, Bloo
Page 801 and 802:
GAL3 86202 Interpretation: Values b
Page 803 and 804:
GGT 8677 common in those of eastern
Page 805 and 806:
GANC 80140 GM1B 83189 Ganciclovir,
Page 807 and 808:
GARL 82760 FGIP 90171 Garlic, IgE C
Page 809 and 810:
GBAMS 60711 gastrin levels (>400 pg
Page 811 and 812:
GAUW 81235 GELA 86326 Interpretatio
Page 813 and 814:
GSNKM 60718 GENPK 84695 Reference V
Page 815 and 816:
GENTT 81591 GERB 82545 Gentamicin,
Page 817 and 818:
GRAB 80628 Clinical Information: Cl
Page 819 and 820:
DGLDN 89031 Clinical Information: C
Page 821 and 822:
DAGL 89029 Clinical References: 1.
Page 823 and 824:
FGLIP disease is associated with a
Page 825 and 826:
GPI 9158 (insulin-dependent diabete
Page 827 and 828:
RGLUR 89847 mellitus which is chara
Page 829 and 830:
GD65S 81596 Clinical Information: H
Page 831 and 832:
GLT 82894 Reference Values:
Page 833 and 834:
GOAT 82783 Class IgE kU/L Interpret
Page 835 and 836:
9810 9812 FGNRH 90165 immune respon
Page 837 and 838:
GWEE 82378 GRAM 8078 6 > or =100 St
Page 839 and 840:
GRFR 82836 clinical manifestations.
Page 841 and 842:
GRAS2 81707 GRAS3 81708 5 50.0-99.9
Page 843 and 844:
GCBN 82769 and to define the allerg
Page 845 and 846:
GPEA 82887 GPEP 82623 Company, 2007
Page 847 and 848:
ALDR 82671 Reference Values: Class
Page 849 and 850:
GRHKM 50038 hyperoxalurias. Kidney
Page 851 and 852:
FIRGH 90161 FGCU 57482 Reference Va
Page 853 and 854:
GUAV 82357 GUIN 82706 Clinical Refe
Page 855 and 856:
FHAD2 91965 HIBS 83261 likelihood o
Page 857 and 858:
HALI 82633 HALO 80339 Halibut, IgE
Page 859 and 860:
FHAN 90405 the concentration of IgE
Page 861 and 862:
HAZ 82670 responsible for eliciting
Page 863 and 864:
HMSBR 34506 Interpretation: The ref
Page 865 and 866:
exposure. Absorbed arsenic is rapid
Page 867 and 868:
HMHA 45479 HMNA 31070 SHELA 84409 H
Page 869 and 870:
SHELI 80668 or =1.00 (positive) Ig
Page 871 and 872:
UBT 81590 Useful For: As an aid in
Page 873 and 874:
EXHB 60562 EXHBM 60558 HLLFH 34854
Page 875 and 876:
9819 FHME 57485 HCASC 34626 anticip
Page 877 and 878:
HBA1C 82080 H63D is insufficient to
Page 879 and 880:
HBELC 81626 Hgb S/beta thalassemia
Page 881 and 882:
HPFH 8270 SFMON 60205 3-5 months: 1
Page 883 and 884:
UNHB 9095 HAEVP 84157 Interpretatio
Page 885 and 886:
FIXMS 84209 Clinical Information: H
Page 887 and 888:
UHSD 8582 HEPN 80609 *Alternative r
Page 889 and 890:
of thrombocytopenia can be rapid (w
Page 891 and 892:
HAV 83330 Useful For: Diagnosis of
Page 893 and 894:
HBC 8347 CORAB 32111 are negative D
Page 895 and 896:
HEPB 200905 Negative HEPATITIS Bs A
Page 897 and 898:
HBAB 8254 Interpretation: Please re
Page 899 and 900:
HBVQU 88634 (HBV) infection, or chr
Page 901 and 902:
FHBGT 57478 FHBSA 57489 HEAB 80973
Page 903 and 904:
HBGCD 83626 HCVPS 13009 Hepatitis B
Page 905 and 906:
HCPCR 60707 Hepatitis C Antibody Sc
Page 907 and 908:
FHFIB 91402 Reference Values: Negat
Page 909 and 910:
HCCAD 87858 versus 24 weeks), patie
Page 911 and 912:
QHCV 81130 Telaprevir-containing Co
Page 913 and 914:
HEPP 200080 Reference Values: Refer
Page 915 and 916:
FHER 91518 FHER2 81954 false-negati
Page 917 and 918:
FH2MT 60655 In much the same way as
Page 919 and 920:
HEMP 61337 Reference Values: Report
Page 921 and 922:
HHTP 89394 Telangiectasia, ENG and
Page 923 and 924:
ENGK 89391 that HHT1 has a more sev
Page 925 and 926:
HPKM 88691 endometrium, and stomach
Page 927 and 928:
FHRIN 91450 VDER 82048 Useful For:
Page 929 and 930:
HSVG 84429 A negative result does n
Page 931 and 932:
FHSAB 57434 FHERV 57305 cerebrospin
Page 933 and 934:
HERR 82823 IgM 85% of the populatio
Page 935 and 936:
MUGS 80350 2 0.70-3.49 Positive 3 3
Page 937 and 938:
NAGW 8775 percent hexosaminidase A
Page 939 and 940:
NAGS 8774 disease carrier identific
Page 941 and 942:
HIPA 9756 FHISP 57275 FHISU 57207 p
Page 943 and 944:
SHSTO 26692 CHIST 8230 HISTO 83853
Page 945 and 946:
HBRPB 60751 HIV2F 80443 management
Page 947 and 948:
HV1CD 83628 HIV antibody test resul
Page 949 and 950:
HIVFA 81758 FHIVD 91901 Negative Se
Page 951 and 952:
GHIVR 88782 Reference Values: Not a
Page 953 and 954:
HIQGP 89402 indicated that detectio
Page 955 and 956:
HIVQR 13035 Clinical References: 1.
Page 957 and 958:
WBANF 32466 low or undetectable HIV
Page 959 and 960:
HIVE 9333 indicates infection with
Page 961 and 962:
HIV2M 60356 FHV2Q 91490 Clinical Re
Page 963 and 964:
DISII 32864 HLA15 89347 transplant
Page 965 and 966:
HL57O 60347 Based on DNA sequence v
Page 967 and 968:
HMBSK 61217 dominant disorder with
Page 969 and 970:
HCYSU 80378 deficiency of B12 and f
Page 971 and 972:
HVAR 60275 HUNY 82373 Medical. Edit
Page 973 and 974:
HOP 82370 1 0.35-0.69 Equivocal 2 0
Page 975 and 976:
HORM 82375 bronchospasm) in infants
Page 977 and 978:
HFSF 82608 DF 82905 6 > or =100 Str
Page 979 and 980:
HD1 81877 sensitization to particul
Page 981 and 982:
HDHS 82903 FHPVG 57480 House Dust/H
Page 983 and 984:
THCG 80678 HHV6 87532 Human Chorion
Page 985 and 986:
FHMPV 91433 BHPV 83344 sequences ha
Page 987 and 988:
60483 FHPL 91178 HTLVL 83277 along
Page 989 and 990:
HTLVI 9539 Diagn Lab Immunol 1998;5
Page 991 and 992:
FHISS 91370 > or =0.50 IU/mL Protec
Page 993 and 994:
HD 61622 CORD BLOOD 510 - 1275 0 0
Page 995 and 996:
FHYDC 90293 HYD18 80744 Performed B
Page 997 and 998:
have demonstrated progressive incre
Page 999 and 1000:
FHPEP 57369 oxalic and glyceric aci
Page 1001 and 1002:
SAL 8768 HYPOG 82439 Hypersensitivi
Page 1003 and 1004:
61207 IDNS 80945 Clinical Reference
Page 1005 and 1006:
IGAS 87938 individuals with food al
Page 1007 and 1008:
IGGS 9259 Adults 288-736 512 Test P
Page 1009 and 1010:
FIG4F 91936 FIMRG 87995 synthesis o
Page 1011 and 1012:
FICEP 91172 levels of imipramine an
Page 1013 and 1014:
FISP 91624 IMFXO Immune Status Pane
Page 1015 and 1016:
IGD 9272 Algorithm in Special Instr
Page 1017 and 1018:
FLCP 84190 IGG 8160 Immunoglobulin
Page 1019 and 1020:
BCGBM 31141 BCGRV 31142 lymphoproli
Page 1021 and 1022:
TLCU 87934 Clinical Information: Th
Page 1023 and 1024:
FIMMC 57370 FUIQL 57488 13-
Page 1025 and 1026:
89067 IgA and IgG ASCA, PV of 90%.(
Page 1027 and 1028:
PROD 60552 Interpretation: The pres
Page 1029 and 1030:
800167 Influenza Virus Type A and T
Page 1031 and 1032:
INHA 81049 Inhibin A, Tumor Marker,
Page 1033 and 1034:
INHU 82789 Marker, Serum. For monit
Page 1035 and 1036:
FINS 81728 INS 8664 Interpretation:
Page 1037 and 1038:
(breast, colon, prostate, lung), an
Page 1039 and 1040:
8 years 70-344 44 9 years 81-389 52
Page 1041 and 1042:
IGF1 15867 antibodies: a problem fo
Page 1043 and 1044:
36-40 years 106-277 41-45 years 98-
Page 1045 and 1046:
emains controversial. Elevated seru
Page 1047 and 1048:
FINTA 91708 FINTB 91719 BIL28 61702
Page 1049 and 1050:
FIL10 91653 FIL2 90481 interpreted
Page 1051 and 1052:
IMAX 5347 IFBA 9335 UIOD 9549 Inter
Page 1053 and 1054:
FIPEC 91134 FEC 34624 Clinical Info
Page 1055 and 1056:
absorption and progressive iron dep
Page 1057 and 1058:
IA2 89588 FISLC 57306 Clinical Refe
Page 1059 and 1060:
IMDI 82774 caused by the release of
Page 1061 and 1062:
INHP 9768 IVD 83644 1 0.35-0.69 Equ
Page 1063 and 1064:
ITCON 81247 JACK 82371 Itraconazole
Page 1065 and 1066:
JAKXB 89189 JAKXM 4 17.5-49.9 Stron
Page 1067 and 1068:
JAK2M 31155 thrombocythemia (25%-55
Page 1069 and 1070:
JCEDR 82865 JMIL 82831 2005;106:120
Page 1071 and 1072:
LCJC 88909 immunocompromised would
Page 1073 and 1074:
9889 JUNE 82893 2 0.70-3.49 Positiv
Page 1075 and 1076:
FKAN 90069 KETAU 89443 FKEBS 91887
Page 1077 and 1078:
KIDBN 82619 CASA DeSilvio M, Khor L
Page 1079 and 1080:
82266 89670 88956 in normal tissues
Page 1081 and 1082:
88955 89669 Cancer 2004;40:689-695
Page 1083 and 1084:
KPCRP 89675 Clinical Information: U
Page 1085 and 1086:
GALCK 60695 KRAS 89378 Krabbe Disea
Page 1087 and 1088:
specificity is derived from the fac
Page 1089 and 1090:
LAA 8665 FLACT 91560 untreated pern
Page 1091 and 1092:
LAMB 82699 0 Negative 1 0.35-0.69 E
Page 1093 and 1094:
LAMO 80999 RDS is inversely related
Page 1095 and 1096:
FLTX 57118 LATX 82787 5 50.0-99.9 S
Page 1097 and 1098:
significantly since the introductio
Page 1099 and 1100:
PBU 8600 LEADB 300098 blood lead re
Page 1101 and 1102:
PBNA 89857 PBRU 60246 Clinical Info
Page 1103 and 1104:
LEFLU 60292 Reference Values: CHOLE
Page 1105 and 1106:
LEGI 8204 SLEG 8122 Fraser DW, Tsai
Page 1107 and 1108:
LEIS 86219 LEM 82678 the Associatio
Page 1109 and 1110:
LEPD 82849 FLEP 91339 5 50.0-99.9 S
Page 1111 and 1112:
LEUC 9771 LCMS 3287 immune response
Page 1113 and 1114:
LEVE 83140 Clinical Information: Le
Page 1115 and 1116:
FLIMB 91635 LIME 82360 Therapeutic
Page 1117 and 1118:
LINS 86311 Class IgE kU/L Interpret
Page 1119 and 1120:
BFLAC 34622 LPSC 8053 > or =16 year
Page 1121 and 1122:
LIPA 81558 available from multiple
Page 1123 and 1124:
LMPP 83673 Lipoprotein Metabolism P
Page 1125 and 1126:
FLIS 90717 FLIST 90048
Page 1127 and 1128:
LOB 82744 LORAZ 80459 HA: Autoantib
Page 1129 and 1130:
LUPN 82613 exhibiting ALK rearrange
Page 1131 and 1132:
LH 8663 0.9-1.2 The INR is used onl
Page 1133 and 1134:
9861 9956 PBORR 80574 syndrome. Pos
Page 1135 and 1136:
FBBIA 91898 FBBAB 91309 LYWB 9535 b
Page 1137 and 1138:
FBBC6 91899 inflammation around the
Page 1139 and 1140:
CLYME 83856 FLASC 57281 LPMAF 60593
Page 1141 and 1142:
LPAGF 60592 1-infected patients: to
Page 1143 and 1144:
decrease in proliferation of only a
Page 1145 and 1146:
LSDU 81743 LPC 83399 Lysergic Acid
Page 1147 and 1148:
lipid component of myelin. The abse
Page 1149 and 1150:
LYZKM 60720 MUR 8507 Edited by S Sa
Page 1151 and 1152:
MACE 82492 Interpretation: ImmunoCA
Page 1153 and 1154:
MGFT 60030 symptoms of hyperprolact
Page 1155 and 1156:
MGRU 60245 likely source of such ex
Page 1157 and 1158:
MGCRU 60244 FMASC 90054 Magnesium/C
Page 1159 and 1160:
MAAN 82396 Clinical Information: Ma
Page 1161 and 1162:
MAND 82352 MNU 8080 5 50.0-99.9 Str
Page 1163 and 1164:
igidity, with increased scores on t
Page 1165 and 1166:
MNCRU 60027 Clinical Information: M
Page 1167 and 1168:
MBL 81051 FMPLE 57188 York, Chapter
Page 1169 and 1170:
MARE 82141 constitutes tau-positive
Page 1171 and 1172:
MCC 88636 9230 9829 Reference Value
Page 1173 and 1174:
MFOX 82914 identify allergens which
Page 1175 and 1176:
ME2KM 89285 are reported in males,
Page 1177 and 1178:
MCADK 83934 patients, approximately
Page 1179 and 1180:
FMELT 57120 MELN 82762 sensitizatio
Page 1181 and 1182:
Reference Range: IgG
Page 1183 and 1184:
FMCPC 57437 Diagnosis of central ne
Page 1185 and 1186:
This test was developed and its per
Page 1187 and 1188:
Reference Range:
Page 1189 and 1190:
St. Louis encephalitis virus throug
Page 1191 and 1192:
MEPHS 83778 FMERC 91120 HGOM 82755
Page 1193 and 1194:
HGHAR 8498 eliciting a proliferatio
Page 1195 and 1196:
METAF 83006 antibodies interact wit
Page 1197 and 1198:
PMET 81609 60-69 years: 138-521 mcg
Page 1199 and 1200:
patients from those with tumor-indu
Page 1201 and 1202:
MTDNS 83131 Useful For: Monitoring
Page 1203 and 1204:
METR 9322 MEVP 84159 other causes,
Page 1205 and 1206:
FMMD 57307 MMAAF 81921 Test Perform
Page 1207 and 1208:
MMAS 80289 Useful For: Evaluating c
Page 1209 and 1210:
MAHKM 89135 Clinical Information: M
Page 1211 and 1212:
MHDKM 61098 Carrier screening in ca
Page 1213 and 1214:
FMI2 57186 RMA 81260 diminished or
Page 1215 and 1216:
MPSF 82515 studies have shown that
Page 1217 and 1218:
MTBS 81507 microsatellite instabili
Page 1219 and 1220:
PMLK 82827 the concentration of IgE
Page 1221 and 1222:
IHCO 29004 Mismatch Repair (MMR) Pr
Page 1223 and 1224:
FMITO 91130 MLH1H 87978 Mitotane (L
Page 1225 and 1226:
MLHKM 83002 mutation. In cases wher
Page 1227 and 1228:
MLH12 83191 MLH1/MSH2 Mutation Scre
Page 1229 and 1230:
MOLD1 81878 MINT 61696 Interpretati
Page 1231 and 1232:
MOLUR 89473 MOLPS 89270 Molybdenum,
Page 1233 and 1234:
FMNM 91829 inhibition of xanthine o
Page 1235 and 1236:
found on protein electrophoresis (P
Page 1237 and 1238:
Clinical Information: Serum protein
Page 1239 and 1240:
MDCG 86880 MORP 83132 complement ca
Page 1241 and 1242:
MOTH 82738 2 0.70-3.49 Positive 3 3
Page 1243 and 1244:
MOUS 82707 4 17.5-49.9 Strongly pos
Page 1245 and 1246:
9832 MPLB 89776 Useful For: Testing
Page 1247 and 1248:
MSH2M 83016 dependent on the gene i
Page 1249 and 1250:
MSH6M 83723 Useful For: Diagnostic
Page 1251 and 1252:
9831 MCIV 85321 MPSSC 84464 disorde
Page 1253 and 1254: adaptive skills. Death generally oc
Page 1255 and 1256: MUG 82683 Clinical Information: Cli
Page 1257 and 1258: MENKM 81082 1 0.35-0.69 Equivocal 2
Page 1259 and 1260: FMUMM 91456 CMUMP Interpretation: O
Page 1261 and 1262: MMPG 82431 MMPM 80977 IgM Negative
Page 1263 and 1264: FMUSK 91445 MSTD 82801 sensitizatio
Page 1265 and 1266: FHST 91957 FHIST 90018 FHSAG 90017
Page 1267 and 1268: MGEP 83371 found in 13% of patients
Page 1269 and 1270: MGLES 83369 neurological complicati
Page 1271 and 1272: CTB 8205 CTBBL 82443 VA: Lambert-Ea
Page 1273 and 1274: MTBRP 88807 MTBPZ 56099 Mycobacteri
Page 1275 and 1276: MPA 81563 MGRP 60755 intermediate t
Page 1277 and 1278: FMPAB 90055 MPC 80422 that has been
Page 1279 and 1280: FMYEL 90476 FMDS 84387 Reference ra
Page 1281 and 1282: MYH 84304 May be useful to follow t
Page 1283 and 1284: MYOS 9035 REFERENCE RANGE: or = 1:
Page 1285 and 1286: FMY3P 57279 FMYO 91544 FCHOP Refere
Page 1287 and 1288: NAT2 83389 Useful For: Assisting in
Page 1289 and 1290: NMHIN 83011 Slow *14G 191G->A 282C-
Page 1291 and 1292: FNAD 80761 FNALO 91784 NARC 82026 N
Page 1293 and 1294: T- and B-CELL QN BY FLOW CYTOMETRY
Page 1295 and 1296: FNEFA 91135 MGRNA 61646 Clinical Re
Page 1297 and 1298: FNMEN 91669 Clinical Information: G
Page 1299 and 1300: NETT 82734 NEURF 88846 Reference Va
Page 1301 and 1302: PNEFS 84300 Bone Marrow Clinical In
Page 1303: PNEFC 84299 Note: Titers lower than
Page 1307 and 1308: NSESF 81796 reference range. Other
Page 1309 and 1310: FNEU 91688 FNTSM 91940 Reference Va
Page 1311 and 1312: NAD 81409 FNIAC 91379 that is unusu
Page 1313 and 1314: NIS 8622 essential for the catalyti
Page 1315 and 1316: NICOS 82509 toxic Ni compounds such
Page 1317 and 1318: NPDMS 61117 Reference Values: Non-t
Page 1319 and 1320: NIEM 9313 NPCKM 83118 Clinical Refe
Page 1321 and 1322: FNIFE 91747 NITF 8909 is a biochemi
Page 1323 and 1324: NMDCC 61513 stromal tumor, pseudopa
Page 1325 and 1326: SSF1 87294 NSIP 31769 Insulin Sensi
Page 1327 and 1328: FNORO 91893 FNLV 91366 NEREG 31767
Page 1329 and 1330: PBNP 84291 Toxic concentration: > o
Page 1331 and 1332: NTXPR 61656 diagnosis and short-ter
Page 1333 and 1334: NUTSP 31771 antibodies interact wit
Page 1335 and 1336: OATS 82688 3 3.50-17.4 Positive 4 1
Page 1337 and 1338: FLNZ 91129 OLIG 8017 sensitivity to
Page 1339 and 1340: FOLRU 91954 OLIV 82733 NY, Springer
Page 1341 and 1342: OPATM 84326 sensitivity to inhalant
Page 1343 and 1344: OPRM1 89612 morphine to codeine can
Page 1345 and 1346: 9836 ORCH 82907 clinical manifestat
Page 1347 and 1348: OAU 80619 0 Negative 1 0.35-0.69 Eq
Page 1349 and 1350: OPTU 83190 metabolism of arginine.
Page 1351 and 1352: UOSMS 9340 UOSMU 9260 Clinical Refe
Page 1353 and 1354: FOVA1 57492 43 and 44. The N-MID-fr
Page 1355 and 1356:
OXI 82679 testing often depend upon
Page 1357 and 1358:
POXA 81408 deficiencies (primary hy
Page 1359 and 1360:
FOXAZ 90108 OMHC 81030 FOXYC 91639
Page 1361 and 1362:
OYST 82883 FPZ 91495 Oyster, IgE Cl
Page 1363 and 1364:
NPAIN 200244 (GC-FID) the following
Page 1365 and 1366:
FPANS 57129 FPANC 91415 HPP 8014 Pr
Page 1367 and 1368:
PAPY 82356 PAPR 82810 Company, 2007
Page 1369 and 1370:
and cellular immune responses to ca
Page 1371 and 1372:
nonorgan-specific antibodies that a
Page 1373 and 1374:
PTH (numbering, by universal conven
Page 1375 and 1376:
parathyroid hormone (PTH) levels. T
Page 1377 and 1378:
PTHRP 81774 from the needle for a s
Page 1379 and 1380:
PJUD 82877 POFF Equivocal: 20.1-24.
Page 1381 and 1382:
PSLY 82765 Interpretation: Steady-s
Page 1383 and 1384:
FPB19 57483 86340 PARVO 83151 1983;
Page 1385 and 1386:
FPCA3 57486 caused by the release o
Page 1387 and 1388:
89671 Interpretation: An interpreta
Page 1389 and 1390:
F512 84463 PECH 82816 imatinib resp
Page 1391 and 1392:
PEAN 82888 PEAR 82807 Peanut, IgE C
Page 1393 and 1394:
PAS38 83346 Reference Values: Class
Page 1395 and 1396:
FPEMC 90120 PBPO 82660 immunoglobul
Page 1397 and 1398:
PENIV 82656 PENL the specific organ
Page 1399 and 1400:
FPCAY 91953 FPEPS 91638 FPERC 91631
Page 1401 and 1402:
PNZN 9789 Clinical Information: Vit
Page 1403 and 1404:
UPHB 9572 FPHFL 57309 PHU_ 9312 rel
Page 1405 and 1406:
PCPU 80371 FPHNZ 90368 PBAR Referen
Page 1407 and 1408:
PKU 8380 Test Performed By: Monogra
Page 1409 and 1410:
PNYFR 9993 30 mcg/mL. Reference Val
Page 1411 and 1412:
PHMA 82736 phenytoin, competes for
Page 1413 and 1414:
natural autoantibodies.(2) Plasma f
Page 1415 and 1416:
CLIPG 87987 an unexplained cutaneou
Page 1417 and 1418:
MCLIP 81900 Interpretation: APL, GP
Page 1419 and 1420:
PPL 8296 PMMIF 89657 Phospholipids,
Page 1421 and 1422:
PHOS 8408 (CDG-Ia or PMM2-CDG) or p
Page 1423 and 1424:
POU 8526 PAHD 82786 Phosphorus, Uri
Page 1425 and 1426:
PIGE 82781 Reference Values: An int
Page 1427 and 1428:
PIGF 82145 Class IgE kU/L Interpret
Page 1429 and 1430:
PINW 9204 immune response to allerg
Page 1431 and 1432:
PISTA 82808 Interpretation: Elevate
Page 1433 and 1434:
PLAI 82837 PBLI 9302 characteristic
Page 1435 and 1436:
newly diagnosed MM and also to dete
Page 1437 and 1438:
PAI1 86083 OXYHEMOGLOBIN > or =12 m
Page 1439 and 1440:
PLAB 8538 PTSE 61749 Interpretation
Page 1441 and 1442:
FPM1 90192 PMLR 84114 3 3.50-17.4 P
Page 1443 and 1444:
PMS2K 61174 Genetics and Genomics (
Page 1445 and 1446:
SPN 8047 FPOLC 57265 sensitive (21%
Page 1447 and 1448:
GAAKM 89897 involvement, and rate o
Page 1449 and 1450:
FPORK 91935 PREGI 82691 5 50.0-99.9
Page 1451 and 1452:
PBGDW 31894 PBGD_ 88925 Porphobilin
Page 1453 and 1454:
PEWE 31893 has additional questions
Page 1455 and 1456:
Clinical Information: The porphyria
Page 1457 and 1458:
PFR 28117 Algorithm and Porphyria (
Page 1459 and 1460:
PQNU 8562 porphyria and porphyria c
Page 1461 and 1462:
PTP 8731 Males: < or =230 nmol/24 h
Page 1463 and 1464:
POSV 9205 PMSBB 81931 range if the
Page 1465 and 1466:
NAK 8468 KFT 60031 spectrometry for
Page 1467 and 1468:
RKUR 84475 carbohydrates passing th
Page 1469 and 1470:
FPOTW 92002 PWDNA 81153 Reference V
Page 1471 and 1472:
17PRN 88646 taking recommended dail
Page 1473 and 1474:
PREGN 88645 16-17 years:
Page 1475 and 1476:
FPAP2 91198 Premature Adrenarche Pr
Page 1477 and 1478:
PAD 81424 increase to 60-400 betwee
Page 1479 and 1480:
PBPR blood and vaginal secretions;
Page 1481 and 1482:
PA 8683 likelihood of allergic dise
Page 1483 and 1484:
FPNTS 57311 PGSN 8141 levels in sep
Page 1485 and 1486:
GRNMS 89188 GRNKM 89187 Progranulin
Page 1487 and 1488:
PRLPM 84462 PRL cutoff results in a
Page 1489 and 1490:
PHD2 61683 FPHEG 90101 deficiency(i
Page 1491 and 1492:
FPRTG 91565 6-mercaptopurine. Metab
Page 1493 and 1494:
FPPOX 57140 FPRSG 57149 FPGD2 90154
Page 1495 and 1496:
SPSA 82023 previously diagnosed pro
Page 1497 and 1498:
FPSAU 91817 PACP 8019 biopsy does n
Page 1499 and 1500:
CFX 9339 2 0.70-3.49 Positive 3 3.5
Page 1501 and 1502:
S_FX 80775 Clinical References: 1.
Page 1503 and 1504:
12PTU 89043 S and C4bBP are coordin
Page 1505 and 1506:
TP 8520 by increased plasma concent
Page 1507 and 1508:
PR3 82965 FPFRG 91503 exercise. Low
Page 1509 and 1510:
PT 9236 Prothrombin Time, Plasma Cl
Page 1511 and 1512:
PPFE 8739 PROTR 9797 CHED The Metab
Page 1513 and 1514:
PCHES 8518 FPTHC 91504 Nelson TC, B
Page 1515 and 1516:
hypertrophic cardiomyopathy (20%-30
Page 1517 and 1518:
PTP22 89315 9901 Tartaglia M, Kalid
Page 1519 and 1520:
PUPY 81420 Useful For: Testing for
Page 1521 and 1522:
PLP 60295 B6PA 61065 30-125 ng/mL p
Page 1523 and 1524:
PK 8659 PYRC 83356 dehydrogenase co
Page 1525 and 1526:
QUAD 81149 of the infection, the ou
Page 1527 and 1528:
QPALM 82863 risk depends on the lev
Page 1529 and 1530:
REPII 82782 ventricular arrhythmia.
Page 1531 and 1532:
RUPR 82148 immunoglobulin E (IgE)-s
Page 1533 and 1534:
RWEED 82616 testing often depend up
Page 1535 and 1536:
RAT 82725 testing often depend upon
Page 1537 and 1538:
RTUP 82794 FRECM 91892 5 50.0-99.9
Page 1539 and 1540:
SORR 82737 Class IgE kU/L Interpret
Page 1541 and 1542:
4986 8104 osmotic and nonosmotic di
Page 1543 and 1544:
PRA 8060 the transplanted kidney (a
Page 1545 and 1546:
RSVAN 110300 RSVP 60550 IgG:
Page 1547 and 1548:
FREB 90331 RBP24 81783 such as vita
Page 1549 and 1550:
RHNI 82856 of polystyrene latex par
Page 1551 and 1552:
VITB2 61637 RIB 87837 virological r
Page 1553 and 1554:
FRCBP 57342 3 3.50-17.4 Positive 4
Page 1555 and 1556:
RNAP 83397 RNP 81357 RNA Polymerase
Page 1557 and 1558:
MARS 82701 sometimes been called "w
Page 1559 and 1560:
ROSC 80262 Clinical Information: Pr
Page 1561 and 1562:
ROC 5194 ROM 80979 Rubeola (Measles
Page 1563 and 1564:
RYEG 82908 2 0.70-3.49 Positive 3 3
Page 1565 and 1566:
AASCA 83022 GASCA 83023 Saccharomyc
Page 1567 and 1568:
SALM 82754 FSMLA 91889 Reference Va
Page 1569 and 1570:
SARD 82818 SCLE 82716 Clinical Refe
Page 1571 and 1572:
SHUR 60451 FSCHC 91781 Interpretati
Page 1573 and 1574:
OXK 8148 SEAFP 31770 Immunology Pri
Page 1575 and 1576:
SECOS 8243 FSEC 90173 FSED 91811 Cl
Page 1577 and 1578:
SEUR 60077 SES 9765 Jun;27(6):662-6
Page 1579 and 1580:
FER 81641 SEMA 9206 Interpretation:
Page 1581 and 1582:
FSMN 91449 SEPTK 61101 1 0.35-0.69
Page 1583 and 1584:
information from both trimesters is
Page 1585 and 1586:
follicle-stimulating hormone (FSH),
Page 1587 and 1588:
HTR2O 60338 pharmacogenetic finding
Page 1589 and 1590:
HTTO 60339 SERU 87834 Clinical Refe
Page 1591 and 1592:
SERWB 84373 Reference values apply
Page 1593 and 1594:
develop. In advanced tumors, morbid
Page 1595 and 1596:
SHBG 9285 and to define the allerge
Page 1597 and 1598:
FSRY 88537 Stage III 13.6 5.8-182 S
Page 1599 and 1600:
Clinical References: Homburger HA:
Page 1601 and 1602:
SCADK 83947 Reference Values: Class
Page 1603 and 1604:
FSHOX 57127 FSHRP 91650 SHRI 82677
Page 1605 and 1606:
BIR 82674 1 0.35-0.69 Equivocal 2 0
Page 1607 and 1608:
SIRO 81768 SM 81358 Sirolimus, Bloo
Page 1609 and 1610:
SMA 6284 Deletion/Duplication, FISH
Page 1611 and 1612:
NABF 8039 NAF 8374 osmolality, and
Page 1613 and 1614:
NAU 8525 sodium) is a predictable c
Page 1615 and 1616:
STFR 84283 SLC1B 61736 autoimmune h
Page 1617 and 1618:
FSOMA 90172 substrates of OATP1B1,
Page 1619 and 1620:
SPAG 8980 SGBF 8275 antibodies inte
Page 1621 and 1622:
SAAS 89882 SAAI 89883 Useful For: D
Page 1623 and 1624:
SPIN 86312 FSMAC 57189 Clinical Ref
Page 1625 and 1626:
FSCA2 91586 FSCA3 91587 FSCA6 91588
Page 1627 and 1628:
SFGP 83679 SPRU 82394 FSCC 57312 fo
Page 1629 and 1630:
SQUID 82631 FSRP 57187 Squid, IgE C
Page 1631 and 1632:
SSB 81359 adenopathy. SS-A/Ro is 1
Page 1633 and 1634:
ST2S 61723 frequency of encephaliti
Page 1635 and 1636:
FSTS 88539 Clinical Information: Cl
Page 1637 and 1638:
INSEC 31765 STBY 82676 Clinical Ref
Page 1639 and 1640:
SPNC 89971 SPNEU 83150 Although the
Page 1641 and 1642:
espond to immunization with unconju
Page 1643 and 1644:
FSTRP 90440 FSTSC 91984 STR 8746 de
Page 1645 and 1646:
FSAI 57313 STCH 9928 FSTYR 91094 Re
Page 1647 and 1648:
SDHSP 89550 involving the telomeres
Page 1649 and 1650:
SDHKM 89554 heterozygous germline m
Page 1651 and 1652:
SDHSB 89551 will probably not resul
Page 1653 and 1654:
SDHSD 89553 corresponding figures a
Page 1655 and 1656:
SUAC 83635 FSUCC 57460 9849 9850 FS
Page 1657 and 1658:
SFZ 8238 testing often depend upon
Page 1659 and 1660:
SUNFS 82813 Reference Values: Inter
Page 1661 and 1662:
poorly understood. Urine supersatur
Page 1663 and 1664:
normal or increased citrate value s
Page 1665 and 1666:
SNS 82594 15-25 mg/kg of body weigh
Page 1667 and 1668:
5581 SGUM 82483 verbal and written
Page 1669 and 1670:
VERG 82909 3 3.50-17.4 Positive 4 1
Page 1671 and 1672:
83361 cell tumors (Ewing sarcoma, a
Page 1673 and 1674:
SGSU 81035 Flunisolide: 0.10 mcg/dL
Page 1675 and 1676:
SYPGN 32184 antibodies, RPR titers
Page 1677 and 1678:
TBNY 82589 may actually represent e
Page 1679 and 1680:
12-17 years: 1,000-2,200 cells/mcL*
Page 1681 and 1682:
6-11 years: 31-47%* 12-17 years: 31
Page 1683 and 1684:
Reference Values: T- AND B-CELL QUA
Page 1685 and 1686:
TCMPF 60588 LYMPHOCYTE RATIO H/S ra
Page 1687 and 1688:
TBBS 9336 0-2 months: 170-1,100 cel
Page 1689 and 1690:
12-17 years: 31-52%* 18-55 years: 3
Page 1691 and 1692:
FRTLP 89040 and trisomy 8 in hepato
Page 1693 and 1694:
TREC 87959 2004;36:1084-1089 T-Cell
Page 1695 and 1696:
TCGR 83122 12-23 months: 620-2,000
Page 1697 and 1698:
TCGRV 31140 TCP 89319 malignancies
Page 1699 and 1700:
CD4+CD62L+CD27+ naive T cells 15-71
Page 1701 and 1702:
TREGS 89318 volunteers: relationshi
Page 1703 and 1704:
FRT3P 600915 et al: CD127 expressio
Page 1705 and 1706:
T3 8613 TUP 81792 Clinical Referenc
Page 1707 and 1708:
FRT4 8725 T4TF 8684 hypothalamic-pi
Page 1709 and 1710:
FFTAP 57299 TARR 82486 immunosuppre
Page 1711 and 1712:
TSD 82588 gangliosides in cells of
Page 1713 and 1714:
FFTEI 91284 FFTEM 80763 TTBS 80065
Page 1715 and 1716:
serum testosterone should still be
Page 1717 and 1718:
pituitary-gonadal feedback involvin
Page 1719 and 1720:
TTFB 83686 > or =19 years: 240-950
Page 1721 and 1722:
kept within the normal female range
Page 1723 and 1724:
symptoms. These may include some de
Page 1725 and 1726:
TTOX 82138 FFTEN 57102 critical iss
Page 1727 and 1728:
skeletal anomalies (chest abnormali
Page 1729 and 1730:
TGFK2 89462 factor-beta receptor ge
Page 1731 and 1732:
THEVP 84158 others. Approximately 2
Page 1733 and 1734:
TLRU 60324 TLCRU 60325 FFTHC 90094
Page 1735 and 1736:
TAMV 82514 TDP 85753 the therapeuti
Page 1737 and 1738:
83343 HPV have been shown to be at
Page 1739 and 1740:
89118 cervical/vaginal cytologic di
Page 1741 and 1742:
FCYNS 57491 FFTHM 90354 Useful For:
Page 1743 and 1744:
FFTHI 91126 TT 9059 g/L) Thiosulfat
Page 1745 and 1746:
THYM 82606 normal function. Acquire
Page 1747 and 1748:
Excision Circles [TREC] Analysis fo
Page 1749 and 1750:
first year and every 6 months in th
Page 1751 and 1752:
TGAB 84382 36-55 years: 142-844 cel
Page 1753 and 1754:
TGFNA 89379 HTG1 83069 Thyroglobuli
Page 1755 and 1756:
THSCM 83633 Clinical Information: S
Page 1757 and 1758:
and Tg autoantibodies in either aut
Page 1759 and 1760:
Clinical Information: Autoimmune th
Page 1761 and 1762:
TIAG 82524 mcg/dL) -Normal TBG of 2
Page 1763 and 1764:
PTICK 83266 FFTIC 91273
Page 1765 and 1766:
FFTIN 91101 TSTGP 83671 Reference V
Page 1767 and 1768:
TTGG 83660 should be referred for s
Page 1769 and 1770:
TIRU 89529 evidence that titanium i
Page 1771 and 1772:
TICRU 89530 independently predict p
Page 1773 and 1774:
TOBR 81751 TOBT 81594 Useful For: M
Page 1775 and 1776:
FFTOL 91122 TOMA 82695 St. Paul, MN
Page 1777 and 1778:
incidence of congenital toxoplasmos
Page 1779 and 1780:
shed oocysts in feces that rapidly
Page 1781 and 1782:
TOXGM 81647 serology assays, antibo
Page 1783 and 1784:
FFTGI 91419 in feces that rapidly m
Page 1785 and 1786:
TRAG 82495 FFTRA 91693 Tragacanth,
Page 1787 and 1788:
TRSF 34623 TACIF 84388 170-340 mg/d
Page 1789 and 1790:
TACIG 89122 Clinical References: 1.
Page 1791 and 1792:
TREE2 81703 sensitization and clini
Page 1793 and 1794:
TREE4 81705 FFTPG 57315 6 > or =100
Page 1795 and 1796:
FFTRE 90306 Trichloroethylene Expos
Page 1797 and 1798:
TRPU 82386 clinical manifestations.
Page 1799 and 1800:
3 weeks of treatment are required b
Page 1801 and 1802:
FFTHE 91109 TMA 82867 Lipids, Lipop
Page 1803 and 1804:
TPPTL 89494 Clinical Information: T
Page 1805 and 1806:
FFTRO 57159 TWRP 80909 345 Oyster P
Page 1807 and 1808:
TROT 82788 Clinical Information: Tr
Page 1809 and 1810:
FFTRF 57317 FFTLI 57318 TRYPA 32283
Page 1811 and 1812:
TRYPU 83823 from 0 to 5 years of ag
Page 1813 and 1814:
FFTUM 91729 TUNA 82547 Reference va
Page 1815 and 1816:
TURK 82702 2 0.70-3.49 Positive 3 3
Page 1817 and 1818:
FFTYS 91855 UBEMS 89919 Tysabri Ant
Page 1819 and 1820:
UGTKO 60351 may cause reduced or ab
Page 1821 and 1822:
UGT2O 60350 UGTI 89397 Clinical Ref
Page 1823 and 1824:
U1A1 83949 transcriptional activity
Page 1825 and 1826:
UEA1 80180 ULCH 82546 UPD 82970 ins
Page 1827 and 1828:
RURAU 89845 URAU 8330 URRP 60758 Ur
Page 1829 and 1830:
URIC 8440 Interpretation: Uric acid
Page 1831 and 1832:
thought to be formed from partially
Page 1833 and 1834:
UPGDW 31892 obstruction. Hemoglobin
Page 1835 and 1836:
UPGC 80288 FURO 81975 0.80-0.99 Rel
Page 1837 and 1838:
USNU 82388 89219 in aneurysmal bone
Page 1839 and 1840:
VPA 8707 VU 83395 Clinical Referenc
Page 1841 and 1842:
VCRU 60575 which most is excreted i
Page 1843 and 1844:
VANCT 81592 recommended for therape
Page 1845 and 1846:
VH 9254 sensitization and clinical
Page 1847 and 1848:
VMAR 60274 FVAP 91277 FVZD 91752 VZ
Page 1849 and 1850:
VZM 80964 are at risk of suffering
Page 1851 and 1852:
VIP 8150 VDRL 80632 VDSF 9028 Vasoa
Page 1853 and 1854:
9945 VLCMS 60036 Venlafaxine is sig
Page 1855 and 1856:
VIGA 91089 VIRNR 87266 Clinical Inf
Page 1857 and 1858:
function of the retina (adaptation
Page 1859 and 1860:
FB12 9156 Vitamin B12 and Folate, S
Page 1861 and 1862:
FB12V 90431 FPAB 57394 800-2600 pg/
Page 1863 and 1864:
FBIOT 91902 VITE 60297 FVIK1 Vitami
Page 1865 and 1866:
VLTB 89190 VLTS 8632 Volatile Scree
Page 1867 and 1868:
VHLD 89211 Cutoff concentration: 10
Page 1869 and 1870:
VHLKP 89084 erythrocytosis or polyc
Page 1871 and 1872:
VWFX 89792 X-linked recessive disor
Page 1873 and 1874:
serves as a carrier protein for coa
Page 1875 and 1876:
VWF serves as an adhesive protein i
Page 1877 and 1878:
FPIKE 91662 WALN 82732 monitoring:
Page 1879 and 1880:
Clinical Information: Warfarin is a
Page 1881 and 1882:
polymorphism in order to maintain t
Page 1883 and 1884:
WMEL 86304 responsible for elicitin
Page 1885 and 1886:
WEED3 81884 Clinical Information: C
Page 1887 and 1888:
WNV 84186 1 0.35-0.69 Equivocal 2 0
Page 1889 and 1890:
WNVP 87802 LCWNV 86197 Clinical Ref
Page 1891 and 1892:
WEEP 83156 IgM: or =1:10 indicates
Page 1893 and 1894:
FWHT4 91978 WHT 82686 Wheat IgG4 Re
Page 1895 and 1896:
BENW 82726 immunoglobulin E (IgE)-s
Page 1897 and 1898:
WHIC 82719 2 0.70-3.49 Positive 3 3
Page 1899 and 1900:
FWHFS 91961 FER2 8893 wheat protein
Page 1901 and 1902:
WSCR 81163 testing often depend upo
Page 1903 and 1904:
WDKM 83698 WDMS 83697 Company, 2007
Page 1905 and 1906:
FBUCC 8668 Clinical Information: Cl
Page 1907 and 1908:
XAN 80313 protein expression, albei
Page 1909 and 1910:
FXAB 57321 Reference Values: Report
Page 1911 and 1912:
FYSTG 92000 YFHV 82657 Italy. J Cli
Page 1913 and 1914:
ZAP70 83727 9864 NEZPP Immunoblot R
Page 1915 and 1916:
ZNRU 60526 FZRBC 91949 Reference va
Page 1917 and 1918:
FZIP 57107 ZONI 83685 minor, second
Page 1919:
one marrow transplantation compatib
show all

Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

Create successful ePaper yourself

Delete template?

Save as template?